|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CELF2 |
Gene summary for CELF2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CELF2 | Gene ID | 10659 |
| Gene name | CUGBP Elav-like family member 2 | |
| Gene Alias | BRUNOL3 | |
| Cytomap | 10p14 | |
| Gene Type | protein-coding | GO ID | GO:0000245 | UniProtAcc | O95319 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10659 | CELF2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.19e-24 | -7.42e-01 | 0.0155 |
| 10659 | CELF2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.36e-13 | -8.02e-01 | -0.1808 |
| 10659 | CELF2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.87e-04 | -4.72e-01 | -0.0811 |
| 10659 | CELF2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.75e-05 | -6.45e-01 | -0.1207 |
| 10659 | CELF2 | HTA11_83_2000001011 | Human | Colorectum | SER | 4.34e-02 | -5.47e-01 | -0.1526 |
| 10659 | CELF2 | HTA11_696_2000001011 | Human | Colorectum | AD | 3.42e-08 | -4.36e-01 | -0.1464 |
| 10659 | CELF2 | HTA11_866_2000001011 | Human | Colorectum | AD | 1.27e-06 | -4.27e-01 | -0.1001 |
| 10659 | CELF2 | HTA11_2992_2000001011 | Human | Colorectum | SER | 4.14e-03 | -7.96e-01 | -0.1706 |
| 10659 | CELF2 | HTA11_5212_2000001011 | Human | Colorectum | AD | 8.12e-03 | -6.72e-01 | -0.2061 |
| 10659 | CELF2 | HTA11_8622_2000001021 | Human | Colorectum | SER | 4.44e-04 | -7.27e-01 | 0.0528 |
| 10659 | CELF2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 4.30e-05 | -3.72e-01 | 0.0674 |
| 10659 | CELF2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.25e-10 | -4.06e-01 | 0.294 |
| 10659 | CELF2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.74e-02 | -2.22e-01 | 0.3859 |
| 10659 | CELF2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 6.61e-17 | -5.65e-01 | 0.3005 |
| 10659 | CELF2 | A015-C-203 | Human | Colorectum | FAP | 1.52e-27 | -3.33e-01 | -0.1294 |
| 10659 | CELF2 | A014-C-040 | Human | Colorectum | FAP | 1.30e-02 | -1.35e-02 | -0.1184 |
| 10659 | CELF2 | A002-C-201 | Human | Colorectum | FAP | 2.05e-10 | -2.01e-02 | 0.0324 |
| 10659 | CELF2 | A001-C-119 | Human | Colorectum | FAP | 3.96e-05 | -3.11e-01 | -0.1557 |
| 10659 | CELF2 | A001-C-108 | Human | Colorectum | FAP | 2.23e-12 | -2.28e-01 | -0.0272 |
| 10659 | CELF2 | A002-C-205 | Human | Colorectum | FAP | 1.14e-23 | -4.46e-01 | -0.1236 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190331133 | Oral cavity | NEOLP | regulation of mRNA metabolic process | 91/2005 | 288/18723 | 2.65e-22 | 7.88e-19 | 91 |
| GO:004348434 | Oral cavity | NEOLP | regulation of RNA splicing | 61/2005 | 148/18723 | 5.56e-22 | 1.10e-18 | 61 |
| GO:005068433 | Oral cavity | NEOLP | regulation of mRNA processing | 56/2005 | 137/18723 | 4.37e-20 | 6.48e-17 | 56 |
| GO:000838033 | Oral cavity | NEOLP | RNA splicing | 110/2005 | 434/18723 | 2.29e-18 | 2.72e-15 | 110 |
| GO:004802433 | Oral cavity | NEOLP | regulation of mRNA splicing, via spliceosome | 44/2005 | 101/18723 | 2.43e-17 | 2.06e-14 | 44 |
| GO:000037733 | Oral cavity | NEOLP | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 81/2005 | 320/18723 | 7.96e-14 | 2.63e-11 | 81 |
| GO:000039833 | Oral cavity | NEOLP | mRNA splicing, via spliceosome | 81/2005 | 320/18723 | 7.96e-14 | 2.63e-11 | 81 |
| GO:000037533 | Oral cavity | NEOLP | RNA splicing, via transesterification reactions | 81/2005 | 324/18723 | 1.64e-13 | 5.13e-11 | 81 |
| GO:007182634 | Oral cavity | NEOLP | ribonucleoprotein complex subunit organization | 60/2005 | 227/18723 | 1.98e-11 | 2.81e-09 | 60 |
| GO:000038031 | Oral cavity | NEOLP | alternative mRNA splicing, via spliceosome | 30/2005 | 77/18723 | 8.63e-11 | 9.32e-09 | 30 |
| GO:002261834 | Oral cavity | NEOLP | ribonucleoprotein complex assembly | 57/2005 | 220/18723 | 1.46e-10 | 1.43e-08 | 57 |
| GO:002261333 | Oral cavity | NEOLP | ribonucleoprotein complex biogenesis | 93/2005 | 463/18723 | 1.34e-09 | 9.49e-08 | 93 |
| GO:000038132 | Oral cavity | NEOLP | regulation of alternative mRNA splicing, via spliceosome | 24/2005 | 60/18723 | 3.51e-09 | 2.04e-07 | 24 |
| GO:00063763 | Oral cavity | NEOLP | mRNA splice site selection | 12/2005 | 49/18723 | 4.66e-03 | 2.56e-02 | 12 |
| GO:000024531 | Oral cavity | NEOLP | spliceosomal complex assembly | 16/2005 | 79/18723 | 8.78e-03 | 4.21e-02 | 16 |
| GO:0022613113 | Thyroid | PTC | ribonucleoprotein complex biogenesis | 292/5968 | 463/18723 | 3.24e-44 | 2.05e-40 | 292 |
| GO:0008380113 | Thyroid | PTC | RNA splicing | 273/5968 | 434/18723 | 4.44e-41 | 1.40e-37 | 273 |
| GO:0000375113 | Thyroid | PTC | RNA splicing, via transesterification reactions | 202/5968 | 324/18723 | 6.81e-30 | 3.91e-27 | 202 |
| GO:0000377113 | Thyroid | PTC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 199/5968 | 320/18723 | 2.96e-29 | 1.44e-26 | 199 |
| GO:0000398113 | Thyroid | PTC | mRNA splicing, via spliceosome | 199/5968 | 320/18723 | 2.96e-29 | 1.44e-26 | 199 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CELF2 | SNV | Missense_Mutation | c.637N>T | p.Val213Leu | p.V213L | protein_coding | deleterious(0.02) | benign(0.019) | TCGA-AN-A0XN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| CELF2 | SNV | Missense_Mutation | c.512N>C | p.Leu171Pro | p.L171P | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | ||
| CELF2 | SNV | Missense_Mutation | c.313N>C | p.Glu105Gln | p.E105Q | protein_coding | tolerated(0.06) | benign(0.087) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CELF2 | SNV | Missense_Mutation | c.965T>A | p.Leu322His | p.L322H | protein_coding | tolerated(0.08) | probably_damaging(0.971) | TCGA-E9-A1NE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | ||
| CELF2 | insertion | Nonsense_Mutation | novel | c.826_827insACTGCTAGACTACAGAGAGAGATAATTAGTCACGCTATG | p.Ile276delinsAsnCysTerThrThrGluArgAspAsnTerSerArgTyrVal | p.I276delinsNC*TTERDN*SRYV | protein_coding | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | |||
| CELF2 | SNV | Missense_Mutation | c.872N>T | p.Ala291Val | p.A291V | protein_coding | tolerated(0.17) | possibly_damaging(0.757) | TCGA-A6-A565-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unspecific | 5FU | PD | ||
| CELF2 | SNV | Missense_Mutation | c.113A>G | p.His38Arg | p.H38R | protein_coding | deleterious(0.02) | probably_damaging(0.945) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| CELF2 | SNV | Missense_Mutation | c.1537N>T | p.Arg513Cys | p.R513C | protein_coding | deleterious(0) | possibly_damaging(0.782) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CELF2 | SNV | Missense_Mutation | novel | c.572N>C | p.Met191Thr | p.M191T | protein_coding | tolerated(0.73) | possibly_damaging(0.801) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CELF2 | SNV | Missense_Mutation | c.1496N>A | p.Gly499Asp | p.G499D | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-A004-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |